Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00451321 · ClinicalTrials.gov registry record · Phase 2
TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT00451321 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 88 participants.
The verdict
NCT00451321, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
The purpose of this study is to optimize several multi-dose regimens of otelixizumab, determine the highest biologically active dose, evaluate biomarkers and surrogates of efficacy, and to evaluate the effects of each multi-dose regimen of otelixizumab against standard safety and efficacy parameters.
Interventions
- DRUG Otelixizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2006-07-31 |
| Est. Completion | 2011-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00451321
The ClinicalTrials.gov registry entry for NCT00451321 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Otelixizumab is the first listed.
NCT00451321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00451321 about?
NCT00451321 is a clinical study titled "TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)". The purpose of this study is to optimize several multi-dose regimens of otelixizumab, determine the highest biologically active dose, evaluate biomarkers and surrogates of efficacy, and to evaluate the effects of each multi-dose regimen of otelixizumab against standard safety and efficacy parameters...
What is the current status of trial NCT00451321?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2006-07-31. Estimated completion is 2011-12-01.
What interventions are being tested in trial NCT00451321?
The interventions under investigation include: Otelixizumab (DRUG).
Who is sponsoring clinical trial NCT00451321?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.